LogiCare3PL proudly supports the launch of Soleno Therapeutics' VYKAT™ XR, the first FDA-approved treatment for hyperphagia linked to Prader-Willi syndrome.

BioCare has been recognized in the 2026 Inc. 5000 list for the fourth consecutive year, emphasizing its innovative model in specialty drug distribution.

Reported Tuesday, Apr 14 - 10:33am EDT (TheFly subscription required to read more.)

LogiCare3PL has been selected by Harrow, Inc. as a distribution partner for their ophthalmic disease management solutions, enhancing market outreach.

LogiCare3PL has formed a significant partnership with ChiRhoClin, Inc. to provide specialized distribution for ChiRhoStim®, enhancing patient care in diagnostics.

Harrow (Nasdaq: HROW) has selected LogiCare3PL as its U.S. distribution partner for Harrow's ophthalmic disease management solutions. Effective Feb 1, 2026, LogiCare3PL will provide both non-title logistics and 3PL title distribution across the U.S., meeting Harrow's rapid onboarding needs.LogiCare3PL completed Harrow's onboarding in four weeks, supporting faster, cost-effective market access while maintaining high-touch customer engagement and continuity of supply.

First and only FDA-approved treatment for hyperphagia in Prader-Willi syndrome reaches patients through LogiCare3PL's specialty pharmaceutical logistics platform OLIVE BRANCH, Miss., April 28, 2025 /PRNewswire/ -- LogiCare3PL is proud to support the commercial launch of VYKAT™ XR, Soleno...